Clinical context
In retinal disease, an anatomical response on OCT does not always translate directly into functional improvement. Retinal thickness and fluid should therefore be considered alongside visual acuity, disease duration, outer retinal integrity, injection burden and durability. For chronic disease, it is especially important to know whether benefit persists beyond a short follow-up period and what treatment burden is required.
What was studied
Participants with centre-involved DME and good baseline vision were assigned to aflibercept, laser or observation.
How the evidence was produced
Randomization reduces the influence of known and unknown confounders and makes comparisons between interventions more reliable. Readers should still examine sequence generation, allocation concealment, masking of outcome assessors, the prespecified primary endpoint, losses to follow-up and intention-to-treat analysis. These details determine how confidently an observed difference can be attributed to the intervention.
How to interpret the result
With good vision, close observation and predefined rescue criteria can be a reasonable initial strategy.
The result should be understood as an estimate for the population studied, not a promise of an individual outcome. Statistical and clinical significance, absolute and relative effects, and prespecified and exploratory analyses should be distinguished. When several endpoints or subgroups are reported, the prespecified primary endpoint for which the study was designed usually provides the most reliable inference.
Clinical applicability
The evidence can help frame the expected balance of benefit, risk and visit burden, but it does not establish a universal regimen. Applicability depends on baseline vision, morphological subtype, previous therapy, retreatment rules and rescue treatment. Differences in these details may materially change the effect seen in routine practice.
Limitations
Observation in the trial was frequent and structured. The result does not support missing follow-up and does not apply to eyes with reduced baseline vision.
Beyond the limitations acknowledged by the authors, confidence is affected by sample size, follow-up duration, missing data, choice of comparator and relevance of the outcomes to routine care. Uncommon complications may remain undetected even in a well-conducted study. External validity is reduced when participants, equipment or investigator expertise differ substantially from everyday settings.
What to verify in the source
In the full paper, verify the protocol, eligibility criteria, baseline group characteristics, primary endpoint definition, confidence intervals, adverse events and losses to follow-up. Funding, conflicts of interest, trial registration and consistency between the published analysis and the original plan deserve separate attention. The DOI or source link below provides access to the primary publication for this check.